Traumatic Brain Injury - Pipeline Review, H2 2016

Date: July 30, 2016
Pages: 262
Price:
US$ 2,000.00
License [?]:
Publisher: Global Markets Direct
Report type: Strategic Report
Delivery: E-mail Delivery (PDF)
ID: TFA2C186293EN
Leaflet:

Download PDF Leaflet

Traumatic Brain Injury - Pipeline Review, H2 2016

Summary

Global Markets Direct’s, ‘Traumatic Brain Injury - Pipeline Review, H2 2016’, provides an overview of the Traumatic Brain Injury pipeline landscape.

The report provides comprehensive information on the therapeutics under development for Traumatic Brain Injury, complete with analysis by stage of development, drug target, mechanism of action (MoA), route of administration (RoA) and molecule type. The report also covers the descriptive pharmacological action of the therapeutics, its complete research and development history and latest news and press releases. Additionally, the report provides an overview of key players involved in therapeutic development for Traumatic Brain Injury and features dormant and discontinued projects.

Global Markets Direct’s report features investigational drugs from across globe covering over 20 therapy areas and nearly 3,000 indications. The report is built using data and information sourced from Global Markets Direct’s proprietary databases, company/university websites, clinical trial registries, conferences, SEC filings, investor presentations and featured press releases from company/university sites and industry-specific third party sources. Drug profiles featured in the report undergoes periodic review following a stringent set of processes to ensure that all the profiles are updated with the latest set of information. Additionally, various dynamic tracking processes ensure that the most recent developments are captured on a real time basis.

The report helps in identifying and tracking emerging players in the market and their portfolios, enhances decision making capabilities and helps to create effective counter strategies to gain competitive advantage.

Note: Certain sections in the report may be removed or altered based on the availability and relevance of data.

Scope
  • The report provides a snapshot of the global therapeutic landscape of Traumatic Brain Injury
  • The report reviews pipeline therapeutics for Traumatic Brain Injury by companies and universities/research institutes based on information derived from company and industry-specific sources
  • The report covers pipeline products based on various stages of development ranging from pre-registration till discovery and undisclosed stages
  • The report features descriptive drug profiles for the pipeline products which includes, product description, descriptive MoA, R&D brief, licensing and collaboration details & other developmental activities
  • The report reviews key players involved Traumatic Brain Injury therapeutics and enlists all their major and minor projects
  • The report assesses Traumatic Brain Injury therapeutics based on drug target, mechanism of action (MoA), route of administration (RoA) and molecule type
  • The report summarizes all the dormant and discontinued pipeline projects
  • The report reviews latest news related to pipeline therapeutics for Traumatic Brain Injury
Reasons to buy
  • Gain strategically significant competitor information, analysis, and insights to formulate effective R&D strategies
  • Identify emerging players with potentially strong product portfolio and create effective counter-strategies to gain competitive advantage
  • Identify and understand important and diverse types of therapeutics under development for Traumatic Brain Injury
  • Identify potential new clients or partners in the target demographic
  • Develop strategic initiatives by understanding the focus areas of leading companies
  • Plan mergers and acquisitions effectively by identifying key players and it’s most promising pipeline therapeutics
  • Devise corrective measures for pipeline projects by understanding Traumatic Brain Injury pipeline depth and focus of Indication therapeutics
  • Develop and design in-licensing and out-licensing strategies by identifying prospective partners with the most attractive projects to enhance and expand business potential and scope
  • Modify the therapeutic portfolio by identifying discontinued projects and understanding the factors that drove them from pipeline
Introduction
Global Markets Direct Report Coverage
Traumatic Brain Injury Overview
Therapeutics Development
Pipeline Products for Traumatic Brain Injury - Overview
Pipeline Products for Traumatic Brain Injury - Comparative Analysis
Traumatic Brain Injury - Therapeutics under Development by Companies
Traumatic Brain Injury - Therapeutics under Investigation by Universities/Institutes
Traumatic Brain Injury - Pipeline Products Glance
Clinical Stage Products
Early Stage Products
Traumatic Brain Injury - Products under Development by Companies
Traumatic Brain Injury - Products under Investigation by Universities/Institutes
Traumatic Brain Injury - Companies Involved in Therapeutics Development
ALSP, Inc.
Amarantus Bioscience Holdings, Inc.
Athersys, Inc.
Beech Tree Labs, Inc.
Cognosci, Inc.
Euroscreen S.A.
Intellect Neurosciences, Inc.
Ischemix, Inc.
Karyopharm Therapeutics, Inc.
Kyorin Pharmaceutical Co., Ltd.
Levolta Pharmaceuticals, Inc.
Lixte Biotechnology Holdings, Inc.
Lpath, Inc.
MandalMed, Inc.
Mapreg S.A.S.
Neuralstem, Inc.
Neuren Pharmaceuticals Limited
NeuroNascent, Inc.
Neuronax SAS
NeuroVive Pharmaceutical AB
New World Laboratories, Inc.
Novogen Limited
NuvOx Pharma LLC
Omeros Corporation
PharmatrophiX, Inc.
Phylogica Limited
Prevacus, Inc.
QR Pharma, Inc.
RegeneRx Biopharmaceuticals, Inc.
Remedy Pharmaceuticals, Inc.
Sage Therapeutics, Inc.
SanBio, Inc.
STATegics, Inc.
Stemedica Cell Technologies, Inc.
SynZyme Technologies, LLC
Tetra Discovery Partners LLC
Thera Neuropharma Inc
vasopharm GmbH
VG Life Sciences, Inc.
Traumatic Brain Injury - Therapeutics Assessment
Assessment by Monotherapy Products
Assessment by Combination Products
Assessment by Target
Assessment by Mechanism of Action
Assessment by Route of Administration
Assessment by Molecule Type
Drug Profiles
(levocetirizine dihydrochloride + montelukast sodium) - Drug Profile

2-DG - DRUG PROFILE

ALP-496 - Drug Profile
AMRS-001 - Drug Profile
AST-001 - Drug Profile
AST-002 - Drug Profile
AVL-8168 - Drug Profile
BQ-A - Drug Profile
BTL-slo - Drug Profile
Cell Therapy for Traumatic Brain Injury - Drug Profile
Cell Therapy to Activate hNT-3 for Spinal Cord and Traumatic Brain Injury - Drug Profile
CHEC-7 - Drug Profile
CHEC-9 - Drug Profile
CMX-2043 - Drug Profile
CNB-001 - Drug Profile
COG-1410 - Drug Profile
cyclosporine - Drug Profile
dexamethasone acetate + melatonin - Drug Profile
EPO-Variant - Drug Profile
ESN-502 - Drug Profile
ethinyl estradiol sulfonate - Drug Profile
EUC-001 - Drug Profile
felbamate - Drug Profile
glyburide - Drug Profile
HBI-002 - Drug Profile
HBI-137 - Drug Profile
HBN-1 - Drug Profile
HBN-2 - Drug Profile
HPI-201 - Drug Profile
HPI-363 - Drug Profile
ibudilast - Drug Profile
ICCN-100 - Drug Profile
JM-4 - Drug Profile
KPT-350 - Drug Profile
LB-201 - Drug Profile
LB-205 - Drug Profile
LM-22A4 - Drug Profile
LM11A-31BHS - Drug Profile
Lpathomab - Drug Profile
MAP-4343 - Drug Profile
Monoclonal Antibody for Central Nervous System - Drug Profile
N-acetyl cysteine amide - Drug Profile
ND-478 - Drug Profile
Neu-2000 - Drug Profile
neuregulin-1 - Drug Profile
NNI-370 - Drug Profile
NNZ-2591 - Drug Profile
NSI-189 - Drug Profile
NSI-566 - Drug Profile
NVP-019 - Drug Profile
NVX-428 - Drug Profile
NWL-53 - Drug Profile
NX-210 - Drug Profile
PF-05285401 - Drug Profile
Posiphen - Drug Profile
PRV-002 - Drug Profile
PYC-35 - Drug Profile
PYC-36 - Drug Profile
PYC-38 - Drug Profile
PYC-98 - Drug Profile
R-503 - Drug Profile
RGN-352 - Drug Profile
ronopterin - Drug Profile
SanFlow - Drug Profile
SB-623 - Drug Profile
sepranolone - Drug Profile
Small Molecule to Activate Epsilon PKC for Traumatic Brain Injury - Drug Profile
Small Molecule to Antagonize GPR17 for Central Nervous System Disorders - Drug Profile
Small Molecules for Stroke and Traumatic Brain Injury - Drug Profile
Small Molecules for Traumatic Brain Injury - Drug Profile
Small Molecules to Antagonize TLR-4 for CNS Disorders - Drug Profile
Small Molecules to Inhibit PBR for Traumatic Brain Injury and Neurodegenerative Diseases - Drug Profile
Stem Cell Therapy for Cardiovascular Disease, CNS Disorders, Metabolic Disorders, Respiratory Disease, Infectious Disease and Toxicology - Drug Profile
Stem Cell Therapy for Central Nervous System Disorder - Drug Profile
Stem Cell Therapy for CNS Disorders - Drug Profile
STSE-15 - Drug Profile
SYN-2 - Drug Profile
SYN-NCE - Drug Profile
T-094 - Drug Profile
TauC-3 - Drug Profile
UH-0113 - Drug Profile
UH-0213 - Drug Profile
VG-1177 - Drug Profile
VitalHeme - Drug Profile
VOLT-02 - Drug Profile
ZL-006 - Drug Profile
Traumatic Brain Injury - Dormant Projects
Traumatic Brain Injury - Discontinued Products
Traumatic Brain Injury - Product Development Milestones
Featured News & Press Releases
Appendix
Methodology
Coverage
Secondary Research
Primary Research
Expert Panel Validation
Contact Us
Disclaimer

LIST OF TABLES

Number of Products under Development for Traumatic Brain Injury, H2 2016
Number of Products under Development for Traumatic Brain Injury - Comparative Analysis, H2 2016
Number of Products under Development by Companies, H2 2016
Number of Products under Development by Companies, H2 2016 (Contd..1)
Number of Products under Development by Companies, H2 2016 (Contd..2)
Number of Products under Development by Companies, H2 2016 (Contd..3)
Number of Products under Investigation by Universities/Institutes, H2 2016
Comparative Analysis by Clinical Stage Development, H2 2016
Comparative Analysis by Early Stage Development, H2 2016
Products under Development by Companies, H2 2016
Products under Development by Companies, H2 2016 (Contd..1)
Products under Development by Companies, H2 2016 (Contd..2)
Products under Development by Companies, H2 2016 (Contd..3)
Products under Investigation by Universities/Institutes, H2 2016
Traumatic Brain Injury - Pipeline by ALSP, Inc., H2 2016
Traumatic Brain Injury - Pipeline by Amarantus Bioscience Holdings, Inc., H2 2016
Traumatic Brain Injury - Pipeline by Athersys, Inc., H2 2016
Traumatic Brain Injury - Pipeline by Beech Tree Labs, Inc., H2 2016
Traumatic Brain Injury - Pipeline by Cognosci, Inc., H2 2016
Traumatic Brain Injury - Pipeline by Euroscreen S.A., H2 2016
Traumatic Brain Injury - Pipeline by Intellect Neurosciences, Inc., H2 2016
Traumatic Brain Injury - Pipeline by Ischemix, Inc., H2 2016
Traumatic Brain Injury - Pipeline by Karyopharm Therapeutics, Inc., H2 2016
Traumatic Brain Injury - Pipeline by Kyorin Pharmaceutical Co., Ltd., H2 2016
Traumatic Brain Injury - Pipeline by Levolta Pharmaceuticals, Inc., H2 2016
Traumatic Brain Injury - Pipeline by Lixte Biotechnology Holdings, Inc., H2 2016
Traumatic Brain Injury - Pipeline by Lpath, Inc., H2 2016
Traumatic Brain Injury - Pipeline by MandalMed, Inc., H2 2016
Traumatic Brain Injury - Pipeline by Mapreg S.A.S., H2 2016
Traumatic Brain Injury - Pipeline by Neuralstem, Inc., H2 2016
Traumatic Brain Injury - Pipeline by Neuren Pharmaceuticals Limited, H2 2016
Traumatic Brain Injury - Pipeline by NeuroNascent, Inc., H2 2016
Traumatic Brain Injury - Pipeline by Neuronax SAS, H2 2016
Traumatic Brain Injury - Pipeline by NeuroVive Pharmaceutical AB, H2 2016
Traumatic Brain Injury - Pipeline by New World Laboratories, Inc., H2 2016
Traumatic Brain Injury - Pipeline by Novogen Limited, H2 2016
Traumatic Brain Injury - Pipeline by NuvOx Pharma LLC, H2 2016
Traumatic Brain Injury - Pipeline by Omeros Corporation, H2 2016
Traumatic Brain Injury - Pipeline by PharmatrophiX, Inc., H2 2016
Traumatic Brain Injury - Pipeline by Phylogica Limited, H2 2016
Traumatic Brain Injury - Pipeline by Prevacus, Inc., H2 2016
Traumatic Brain Injury - Pipeline by QR Pharma, Inc., H2 2016
Traumatic Brain Injury - Pipeline by RegeneRx Biopharmaceuticals, Inc., H2 2016
Traumatic Brain Injury - Pipeline by Remedy Pharmaceuticals, Inc., H2 2016
Traumatic Brain Injury - Pipeline by Sage Therapeutics, Inc., H2 2016
Traumatic Brain Injury - Pipeline by SanBio, Inc., H2 2016
Traumatic Brain Injury - Pipeline by STATegics, Inc., H2 2016
Traumatic Brain Injury - Pipeline by Stemedica Cell Technologies, Inc., H2 2016
Traumatic Brain Injury - Pipeline by SynZyme Technologies, LLC, H2 2016
Traumatic Brain Injury - Pipeline by Tetra Discovery Partners LLC, H2 2016
Traumatic Brain Injury - Pipeline by Thera Neuropharma Inc, H2 2016
Traumatic Brain Injury - Pipeline by vasopharm GmbH, H2 2016
Traumatic Brain Injury - Pipeline by VG Life Sciences, Inc., H2 2016
Assessment by Monotherapy Products, H2 2016
Assessment by Combination Products, H2 2016
Number of Products by Stage and Target, H2 2016
Number of Products by Stage and Mechanism of Action, H2 2016
Number of Products by Stage and Route of Administration, H2 2016
Number of Products by Stage and Molecule Type, H2 2016
Traumatic Brain Injury - Dormant Projects, H2 2016
Traumatic Brain Injury - Dormant Projects (Contd..1), H2 2016
Traumatic Brain Injury - Dormant Projects (Contd..2), H2 2016
Traumatic Brain Injury - Dormant Projects (Contd..3), H2 2016
Traumatic Brain Injury - Dormant Projects (Contd..4), H2 2016
Traumatic Brain Injury - Discontinued Products, H2 2016

LIST OF FIGURES

Number of Products under Development for Traumatic Brain Injury, H2 2016
Number of Products under Development for Traumatic Brain Injury - Comparative Analysis, H2 2016
Number of Products under Development by Companies, H2 2016
Number of Products under Investigation by Universities/Institutes, H2 2016
Comparative Analysis by Clinical Stage Development, H2 2016
Comparative Analysis by Early Stage Products, H2 2016
Assessment by Monotherapy Products, H2 2016
Number of Products by Top 10 Targets, H2 2016
Number of Products by Stage and Top 10 Targets, H2 2016
Number of Products by Top 10 Mechanism of Actions, H2 2016
Number of Products by Stage and Top 10 Mechanism of Actions, H2 2016
Number of Products by Top 10 Routes of Administration, H2 2016
Number of Products by Stage and Top 10 Routes of Administration, H2 2016
Number of Products by Molecule Types, H2 2016
Number of Products by Stage and Molecule Types, H2 2016
Skip to top


Brain Injury - Pipeline Review, H1 2015 US$ 1,600.00 Jan, 2015 · 43 pages
Traumatic Brain Injury - Pipeline Insights, 2016 US$ 1,000.00 Nov, 2016 · 60 pages
Reperfusion Injury - Pipeline Review, H2 2014 US$ 1,600.00 Nov, 2014 · 52 pages
Brain Metastasis - Pipeline Review, H2 2015 US$ 1,600.00 Jul, 2015 · 194 pages

Ask Your Question

Traumatic Brain Injury - Pipeline Review, H2 2016
Company name*:
Contact person*:
Phone/fax*:
Email*:
Request invoice
Your enquiry:
Please click on a Check Box below to confirm you are not a robot: